Ralf Gutzmer
#157,602
Most Influential Person Now
Researcher
Ralf Gutzmer's AcademicInfluence.com Rankings
Ralf Gutzmercomputer-science Degrees
Computer Science
#8778
World Rank
#9229
Historical Rank
Computational Linguistics
#2020
World Rank
#2042
Historical Rank
Machine Learning
#3687
World Rank
#3733
Historical Rank
Artificial Intelligence
#3999
World Rank
#4057
Historical Rank
Download Badge
Computer Science
Ralf Gutzmer's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Ralf Gutzmer Influential?
(Suggest an Edit or Addition)Ralf Gutzmer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) (2647)
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (2015) (2259)
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (2015) (2032)
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018) (1137)
- Melanoma (2018) (873)
- The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. (2014) (769)
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (2018) (577)
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. (2016) (528)
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. (2016) (467)
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) (449)
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network (2013) (411)
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (376)
- International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors (2015) (375)
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. (2018) (372)
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. (2017) (347)
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. (2017) (344)
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. (2016) (317)
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. (2017) (312)
- Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. (2015) (310)
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial (2020) (300)
- Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” (2013) (275)
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
- Histamine H4 Receptor Stimulation Suppresses IL-12p70 Production and Mediates Chemotaxis in Human Monocyte-Derived Dendritic Cells 1 (2005) (226)
- Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. (2017) (216)
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo (2020) (212)
- The histamine H4 receptor is functionally expressed on T(H)2 cells. (2009) (205)
- MicroRNA‐15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma (2010) (191)
- Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model (2012) (158)
- Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions (2017) (157)
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. (2013) (153)
- Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. (2019) (151)
- Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas (2008) (144)
- Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. (2017) (143)
- Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study (2017) (138)
- The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. (2016) (135)
- Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. (2008) (135)
- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. (2017) (132)
- Histamine H4 receptor antagonism reduces hapten‐induced scratching behaviour but not inflammation (2009) (132)
- Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial (2020) (126)
- Histamine downregulates monocyte CCL2 production through the histamine H4 receptor. (2007) (123)
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) (119)
- The hand‐foot‐syndrome associated with medical tumor therapy – classification and management (2010) (117)
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial (2020) (116)
- Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. (2008) (112)
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. (2020) (110)
- An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). (2013) (109)
- Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management (2019) (104)
- Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma (2016) (104)
- A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma (2011) (102)
- Histamine H4 receptors modulate dendritic cell migration through skin – immunomodulatory role of histamine (2008) (100)
- Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. (2005) (97)
- Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. (2021) (96)
- Basal cell carcinoma-treatments for the commonest skin cancer. (2014) (95)
- Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. (2018) (88)
- Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders (2018) (88)
- Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. (2018) (88)
- MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. (2018) (85)
- Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study (2019) (82)
- Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma (2002) (80)
- Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing (2020) (79)
- Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. (2015) (78)
- Histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4 receptor. (2013) (77)
- Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook (2019) (77)
- LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY (2014) (76)
- Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion (2020) (76)
- Hedgehog signaling inhibitors in solid and hematological cancers. (2019) (75)
- Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients (2018) (74)
- Sentinel lymph node status is the most important prognostic factor for thick (≥ 4 mm) melanomas (2008) (74)
- Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses (2014) (72)
- Human Dendritic Cells Express the IL-18R and Are Chemoattracted to IL-18 1 (2003) (72)
- Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy (2005) (70)
- microRNA‐21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells (2012) (70)
- Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. (2013) (68)
- Anal Mucosal Melanoma with KIT-Activating Mutation and Response to Imatinib Therapy – Case Report and Review of the Literature (2009) (68)
- Murine and human Langerhans cells express a functional histamine H4 receptor: modulation of cell migration and function (2009) (68)
- Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. (2012) (67)
- Prognostic Significance of Isolated HMB45 or Melan A Positive Cells in Melanoma Sentinel Lymph Nodes (2007) (67)
- Sentinel node biopsy in melanoma delays recurrence but does not change melanoma‐related survival: a retrospective analysis of 673 patients (2005) (66)
- Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. (2012) (64)
- Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. (2017) (63)
- Human memory Th17 cells express a functional histamine H4 receptor. (2012) (62)
- Human monocyte‐derived dendritic cells are chemoattracted to C3a after up‐regulation of the C3a receptor with interferons (2004) (62)
- A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. (2015) (61)
- Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a. (2006) (60)
- Age as a key factor influencing metastasizing patterns and disease‐specific survival after sentinel lymph node biopsy for cutaneous melanoma (2011) (59)
- Therapy of noninfectious granulomatous skin diseases with fumaric acid esters (2005) (59)
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. (2019) (56)
- Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. (2019) (55)
- The histamine H4 receptor is highly expressed on plasmacytoid dendritic cells in psoriasis and histamine regulates their cytokine production and migration. (2011) (55)
- S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version (2013) (55)
- Erythema nodosum‐like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature (2015) (54)
- Pharmacological characterization of the new histamine H4 receptor agonist VUF 8430 (2009) (54)
- Rapid identification and differentiation of fungal DNA in dermatological specimens by LightCycler PCR. (2004) (53)
- Current diagnosis and treatment of basal cell carcinoma (2015) (52)
- S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of‐care indicators (2020) (51)
- Pathogenetic and therapeutic implications of the histamine H4 receptor in inflammatory skin diseases and pruritus. (2011) (51)
- Criteria in Sentinel Lymph Nodes of Melanoma Patients that Predict Involvement of Nonsentinel Lymph Nodes (2008) (49)
- Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. (2019) (48)
- Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. (2008) (48)
- Expression and function of histamine receptors 1 and 2 on human monocyte-derived dendritic cells. (2002) (47)
- Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial. (2021) (46)
- Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. (2014) (46)
- Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low‐dose interferon alpha (2007) (45)
- Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician (2011) (45)
- Life expectancy in primary myelodysplastic syndromes: A prognostic score based upon histopathology from bone marrow biopsies of 569 patients (1994) (45)
- Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study (2016) (44)
- Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). (2019) (44)
- The role of the histamine H4 receptor in atopic dermatitis and psoriasis (2020) (44)
- Sensitive Detection of Borrelia burgdorferi Sensu Lato DNA and Differentiation ofBorrelia Species by LightCycler PCR (2001) (43)
- Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. (2019) (43)
- Histamine H4 receptor activation on human slan‐dendritic cells down‐regulates their pro‐inflammatory capacity (2011) (43)
- Histamine H4 receptor knockout mice display reduced inflammation in a chronic model of atopic dermatitis (2016) (42)
- Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry (2002) (41)
- Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma (2017) (41)
- S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow‐up, prevention and occupational disease (2020) (41)
- Induction of C3 and CCL2 by C3a in Keratinocytes: A Novel Autocrine Amplification Loop of Inflammatory Skin Reactions1 (2006) (41)
- Cutaneous side effects of new antitumor drugs: clinical features and management. (2012) (40)
- Non‐melanoma skin cancer is reduced after switch of immunosuppression to mTOR‐inhibitors in organ transplant recipients (2014) (40)
- Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma (2017) (40)
- Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma (2019) (40)
- Identification of two distinct deletion targets at 11q23 in cutaneous malignant melanoma (1999) (40)
- Comparison of classification systems in melanoma sentinel lymph nodes—An analysis of 697 patients from a single center (2010) (40)
- Medical treatment of advanced cutaneous squamous‐cell carcinoma (2019) (39)
- Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma (2000) (39)
- Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients (2020) (39)
- Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node? (2014) (38)
- Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. (2019) (38)
- The Role of the Histamine H4 Receptor in Atopic Dermatitis (2011) (37)
- Clinics, prognosis and new therapeutic options in patients with mucosal melanoma (2017) (37)
- Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. (2016) (37)
- 1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM). (2014) (36)
- Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. (2013) (36)
- First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis (2019) (36)
- Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies (2002) (35)
- Lentivirus-induced ‘Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma (2015) (35)
- Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. (2018) (35)
- Unilateral laterothoracic exanthem (asymmetrical periflexural exanthem of childhood): report of an adult patient. (1997) (35)
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. (2019) (34)
- Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up (2011) (34)
- Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature. (2017) (33)
- Histamine down‐regulates IL‐27 production in antigen‐presenting cells (2012) (33)
- Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases (2019) (33)
- Melanoma brain metastases - Interdisciplinary management recommendations 2020. (2020) (33)
- Next‐generation sequencing fails to identify human virus sequences in cutaneous squamous cell carcinoma (2012) (33)
- Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update (2020) (33)
- 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) (2021) (32)
- Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D). (2017) (30)
- Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (2020) (30)
- The pattern and clinicopathological correlates of programmed death‐ligand 1 expression in cutaneous squamous cell carcinoma (2017) (29)
- Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. (2015) (28)
- Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients (2018) (28)
- Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. (2020) (28)
- A Tumor-Associated Glycoprotein That Blocks MHC Class II-Dependent Antigen Presentation by Dendritic Cells1 (2004) (28)
- Imiquimod 5% Cream in the Treatment of Human Papillomavirus-16-Positive Erythroplasia of Queyrat (2002) (28)
- Characterisation of Prognosis and Invasion of Cutaneous Squamous Cell Carcinoma by Podoplanin and E-Cadherin Expression (2016) (28)
- Human basophil chemotaxis and activation are regulated via the histamine H4 receptor (2016) (27)
- Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). (2019) (27)
- Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. (2019) (26)
- Up‐regulation of C5a receptor expression and function on human monocyte derived dendritic cells by prostaglandin E2 (2003) (26)
- Profiling of histamine H4 receptor agonists in native human monocytes (2013) (26)
- Colorectal Cancer Vaccines: Antiidiotypic Antibody, Recombinant Protein, and Viral Vector (2000) (26)
- Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions (2014) (26)
- Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients (2020) (26)
- Tumoral melanosis involving the sentinel lymph nodes: a case report (2007) (26)
- Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option? (2017) (26)
- Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. (2019) (25)
- Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. (2011) (25)
- Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) (2021) (24)
- Complete remission of metastatic melanoma upon BRAF inhibitor treatment – what happens after discontinuation? (2015) (24)
- Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. (2015) (23)
- Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma (2015) (23)
- Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. (2018) (23)
- Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma (2021) (23)
- No human virus sequences detected by next‐generation sequencing in benign verrucous skin tumors occurring in BRAF‐inhibitor‐treated patients (2013) (23)
- Detection of clonal T cell receptor gamma gene rearrangements in cutaneous T cell lymphoma by LightCycler-polymerase chain reaction. (2001) (23)
- Palliative treatment of skin metastases in dermato‐oncology (2013) (22)
- Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells (2011) (22)
- Intermittent BRAF‐inhibitor therapy is a feasible option: report of a patient with metastatic melanoma (2014) (21)
- Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group (2008) (21)
- Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers? (2010) (21)
- Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma (2020) (21)
- Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study. (2018) (21)
- Successful Therapy of Annular Elastolytic Giant Cell Granuloma with Fumaric Acid Esters (2002) (21)
- Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma (2017) (21)
- Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma (2015) (21)
- Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. (2019) (21)
- Treatment of Advanced Cutaneous Squamous Cell Carcinomas with Epidermal Growth Factor Receptor Inhibitors (2013) (20)
- Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) (2016) (20)
- Stimulation of the histamine 4 receptor upregulates thymic stromal lymphopoietin (TSLP) in human and murine keratinocytes. (2016) (19)
- Further evidence for ultraviolet light induction of CDKN2 (p16INK4) mutations in sporadic melanoma in vivo. (1997) (19)
- A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. (2015) (19)
- Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry. (2019) (19)
- GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma (2020) (19)
- Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy. (2012) (19)
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) (18)
- Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers (2021) (18)
- Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma (2022) (18)
- Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. (2016) (18)
- Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial. (2010) (17)
- Well characterized antihistamine 4 receptor antibodies contribute to current knowledge of the expression and biology of the human and murine histamine 4 receptor (2012) (17)
- Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. (2021) (17)
- The Anaphylatoxin C3a Receptor Expression on Human M2 Macrophages Is Down-Regulated by Stimulating the Histamine H4 Receptor and the IL-4 Receptor (2018) (17)
- Histamine Downregulates the Th1-Associated Chemokine IP-10 in Monocytes and Myeloid Dendritic Cells (2013) (17)
- Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation (2019) (16)
- PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. (2018) (16)
- Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
- The histamine H4 receptor modulates the differentiation process of human monocyte-derived M1 macrophages and the release of CCL4/MIP-1β from fully differentiated M1 macrophages (2018) (16)
- Actinic Keratosis and Cutaneous Squamous Cell Carcinoma. (2019) (16)
- Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice (2019) (16)
- Fear of cancer progression in patients with stage IA malignant melanoma (2018) (15)
- Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma. (2013) (15)
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma (2022) (15)
- Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. (2019) (14)
- The Histamine H4 Receptor Regulates Chemokine Production in Human Natural Killer Cells (2015) (14)
- Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma. (2019) (14)
- Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC) (2014) (13)
- Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB-IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study. (2018) (13)
- [Cutaneous squamous cell carcinoma: a review with consideration of special patient groups]. (2014) (13)
- Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial. (2010) (13)
- Melanoma and other skin tumors (2012) (13)
- Combined treatment with H1 and H4 receptor antagonists reduces inflammation in a mouse model of atopic dermatitis. (2017) (13)
- The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series. (2018) (13)
- Histamine up‐regulates oncostatin M expression in human M1 macrophages (2019) (13)
- [Cutaneous side effects of EGF-receptor inhibition and their management]. (2006) (12)
- Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition (2010) (12)
- Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy (2016) (12)
- SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry (2020) (12)
- [Cutaneous squamous cell carcinoma]. (2016) (11)
- Spontaneous regression of melanoma with distant metastases - report of a patient with brain metastases. (2006) (11)
- [Successful treatment of skin and lung sarcoidosis with fumaric acid ester]. (2004) (11)
- Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C (2017) (11)
- Critical involvement of IL‐12 in IFN‐γ induction by calcineurin antagonists in activated human lymphocytes (2006) (11)
- Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma (2022) (11)
- Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial) (2013) (11)
- Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes (2016) (11)
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) (2022) (10)
- Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients (2007) (10)
- Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED) (2019) (10)
- Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365 (2012) (10)
- Absence of HHV‐8 DNA in hobnail hemangiomas (2002) (10)
- Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers (2012) (10)
- Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study (2014) (10)
- Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians (2009) (10)
- Gene therapy for melanoma in humans. (1998) (10)
- 1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (10)
- Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408). (2008) (9)
- [Successful topical treatment of cutaneous sarcoidosis with tacrolimus]. (2003) (9)
- Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG (2020) (9)
- COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma (2022) (9)
- Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs) (2021) (9)
- Monocyte-Derived Dendritic Cells Mediates Chemotaxis in Human Suppresses IL-12 p 70 Production and Histamine H 4 Receptor Stimulation (2005) (9)
- Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node-negative patients limit the prognostic value of sentinel node biopsy for head or neck melanomas (2014) (9)
- Alkaptonuric ochronosis: report of two affected brothers. (1997) (9)
- Parameters predicting prognosis in melanoma sentinel nodes. (2011) (9)
- [Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus]. (2012) (8)
- Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma. (2022) (8)
- Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis (2021) (8)
- Willingness to pay for a cure of low-risk melanoma patients in Germany (2018) (8)
- Histamine H2 receptor stimulation upregulates TH2 chemokine CCL17 production in human M2a macrophages. (2017) (8)
- Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis? (2021) (7)
- Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study (2021) (7)
- Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro. (2009) (7)
- Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. (2021) (7)
- Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study. (2020) (7)
- Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. (2021) (7)
- NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. (2021) (7)
- The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes. (2018) (7)
- Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial (2022) (7)
- Which parameters to choose for prediction of non-sentinel lymph node positivity in melanoma? (2011) (7)
- Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients withBRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial (2020) (7)
- Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group. (2021) (7)
- Long-Term Outcomes in Patients With BRAF V 600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy : Analysis From Phase 2 and 3 Clinical Trials (2021) (7)
- Management of primary and metastasized melanoma in Germany in the time period 1976–2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society (2008) (6)
- The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians (2018) (6)
- BRAF Inhibition in a Lung Transplant Recipient With Metastatic Melanoma. (2016) (6)
- Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. (2014) (6)
- The H4R is highly expressed on eosinophils from AD patients and IL‐4 upregulates expression and function via the JAK/STAT pathway (2020) (6)
- BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
- 1125PPATIENT-REPORTED QUALITY OF LIFE (QOL) WITH SONIDEGIB (LDE225) IN ADVANCED BASAL CELL CARCINOMA (BCC). (2014) (5)
- Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients (2021) (5)
- [Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases]. (2009) (5)
- Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study. (2022) (5)
- Enhanced postoperative lymphatic staging of malignant melanoma by endoscopically assisted iliacoinguinal dissection (2012) (5)
- Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy. (2021) (5)
- Genetic variations within the promotor region of the human histamine H4 receptor gene in psoriasis patients. (2016) (5)
- Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis (2021) (5)
- [Giant keratoacanthoma in an immunocompetent patient with detection of HPV 11]. (2009) (5)
- Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe (2018) (5)
- [SAPHO syndrome. Case description of 3 patients with acne conglobata and osteoarticular symptoms]. (1997) (5)
- [Bart syndrome--separate entity or a variant of epidermolysis bullosa?]. (1997) (5)
- Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. (2022) (5)
- Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma (2022) (5)
- [Amicrobial intertriginous pustulosis in autoimmune diseases--a new entity?]. (1998) (5)
- Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma. (2017) (5)
- Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (5)
- Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). (2021) (5)
- Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS (2021) (5)
- Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses. (2014) (4)
- Focal neurological signs and symptoms induced by interferon‐alpha in two patients with malignant melanoma (1997) (4)
- Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma. (2014) (4)
- 1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study (2020) (4)
- [Post-zoster granuloma with detection of varicella zoster virus DNA in the granulomas]. (2001) (4)
- Cutaneous Side Effects of New Antitumor Drugs (2012) (4)
- Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) (4)
- Stimulation of histamine H4 receptors increases the production of IL‐9 in Th9 polarized cells (2019) (4)
- Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma. (2013) (4)
- Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade (2022) (4)
- Histamine 2 Receptor Agonism and Histamine 4 Receptor Antagonism Ameliorate Inflammation in a Model of Psoriasis (2020) (4)
- Histamine Increases Th2 Cytokine-Induced CCL18 Expression in Human M2 Macrophages (2021) (4)
- Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients (2007) (4)
- Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis (2021) (4)
- Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis (2021) (4)
- [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors]. (2014) (4)
- The genetic landscape of clinical resistance to RAF inhibition in melanoma. (2013) (4)
- Adverse events of special interest in the phase 3 COLUMBUS study. (2018) (3)
- Successful treatment of an angiosarcoma of the head – options for systemic therapy (2011) (3)
- Abstract LB-021: Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors (2019) (3)
- Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study. (2022) (3)
- Response rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials (2018) (3)
- Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis (2016) (3)
- Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. (2022) (3)
- Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy (2020) (3)
- Impact of the COVID‐19 pandemic on the care of patients with malignant melanoma (2022) (3)
- [For the benefit of the patient: the sentinel node excision]. (2011) (3)
- Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy (2014) (3)
- The histamine H4 receptor modulates the differentiation process of human monocyte-derived M1 macrophages and the release of CCL4/MIP-1β from fully differentiated M1 macrophages (2018) (3)
- Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells (2021) (3)
- Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma (2021) (3)
- Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. (2017) (3)
- [Cutaneous squamous cell carcinoma]. (2020) (3)
- 1245PQuality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma (2017) (3)
- Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial (2017) (3)
- Real‐world outcomes using PD‐1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland (2022) (3)
- Medikamentöse Tumortherapie (2010) (3)
- MAGE-A3 expression in patients screened for the DERMA trial: A phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma. (2012) (3)
- Histamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (2)
- 787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial (2022) (2)
- Comparison of scoring systems in primary myelodysplastic syndromes (1995) (2)
- Psoriasis vulgaris triggered by treatment with mogamulizumab in a patient with cutaneous T‐cell lymphoma (2021) (2)
- MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG. (2022) (2)
- LBA33RANDOMIZED, DOUBLE-BLIND STUDY OF SONIDEGIB (LDE225) IN PATIENTS (PTS) WITH ADVANCED BASAL CELL CARCINOMA (BCC) (2014) (2)
- Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (2)
- [Squamous cell carcinoma developing in oral lichen planus]. (2013) (2)
- Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. (2022) (2)
- The effect of mogamulizumab on the malignant T cell population: a monocentric retrospective analysis (2022) (2)
- Phase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy (2019) (2)
- A phase II, single-armed, multicenter trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma: NICCI. (2014) (2)
- Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis. (2016) (2)
- 307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study (2020) (2)
- Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study (2021) (2)
- 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma (2021) (2)
- Abstract CT006: Phase 2 study of pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): KEYNOTE-629 (2021) (2)
- Atypical cutaneous herpes virus infection associated with fludarabine chemotherapy of lymphoma. (2007) (2)
- Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany (2022) (2)
- Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) (2020) (2)
- Treatment with two diff erent doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma ( BOLT ) : a multicentre , randomised , double-blind phase 2 trial (2015) (2)
- Randomized phase II study of the safety and efficacy of a human anti-{alpha}v integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results (2016) (2)
- TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy (2022) (2)
- Alkaptonuric ochronosis: brothers Report of two affected (1997) (2)
- Comparison of classification systems in melanoma sentinel nodes: An analysis of 697 patients from a single center. (2010) (2)
- Sirolimus diminishes the expression of GRO-α (CXCL-1) /CXCR2 axis in human keratinocytes and cutaneous squamous cell carcinoma cells. (2021) (1)
- Differential in fl uence of vemurafenib and dabrafenib on patients ’ lymphocytes despite similar clinical ef fi cacy in melanoma (2014) (1)
- [Intravascular lymphoma: two case reports demonstrating the heterogeneity of the disease]. (2009) (1)
- Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma (2020) (1)
- The price of tumor control (2013) (1)
- Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives (2022) (1)
- Expression of histamine receptors H2R and H4R are predominantly regulated via the IL‐4/IL‐13 receptor type II on human M2 macrophages (2021) (1)
- Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study (2022) (1)
- [CNS metastases--an interdisciplinary challenge]. (2013) (1)
- 3347 BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) and evaluation of tumor response using 2 sets of composite assessment criteria (2015) (1)
- Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity (2022) (1)
- FC10 Sorafenib and pegylated interferon alpha 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial (2010) (1)
- Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study (2019) (1)
- 1092PD AN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON (2014) (1)
- Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma. (2020) (1)
- Monoclonal gammopathy with cutaneous significance treated successfully with rituximab (2022) (1)
- Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial. (2014) (1)
- Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence. (2022) (1)
- Aviscumine (ME-503)-Skin Reaction as significant Factor for its Efficacy Expanded Evaluation of the Results from the Phase II Trial NCT00658437 in Patients with Unresectable stage IV Metastatic Melanoma (2017) (1)
- BRAF/MEK inhibition in melanoma patients with rare BRAF mutations. (2018) (1)
- Quality-of-life (QoL) impairment in melanoma patients receiving high-dose interferon alpha 2b (IFNa2b). (2009) (1)
- Histamine down‐regulates the FCERI α‐chain expression in human IL‐4‐activated M2 macrophages (2020) (1)
- Merkel-Zell-Karzinom (2021) (1)
- [Facial pigmentation following therapy with terbinafine]. (2005) (1)
- Checkpoint inhibitor–induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin’s lymphoma (2021) (1)
- [Cutaneous side effects of medical tumor therapy]. (2011) (1)
- [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma]. (2015) (0)
- Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients (2022) (0)
- Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity. (2023) (0)
- Kaposi’s sarcoma P90 Remission of iatrogenic Kaposi’s sarcoma after switch of immunosuppressive regimen to everolimus in a patient with myasthenia gravis (2010) (0)
- Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naive advanced metastastic melanoma (ChemoSensMM): A multicenter randomized phase-3 DeCOG trial. (2015) (0)
- 1122P Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases (2020) (0)
- Response to letter entitled: 'Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors'. (2021) (0)
- The GERMELATOX-A (Dermatologic Cooperative Oncology Group): Study attitude of German melanoma patients towards toxicity during adjuvant treatment. (2022) (0)
- 1079P Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naïve and pretreated patients with advanced melanoma within the German noninterventional study NICO (2021) (0)
- Presentation by Dendritic Cells Blocks MHC Class II-Dependent Antigen A Tumor-Associated Glycoprotein That (2004) (0)
- Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up (2023) (0)
- Functional expression and regulation of the C5a-receptor on human dendritic cells (2000) (0)
- CsA-induced IFN-production of human TCR-stimulated PBMC upon incubation with IL-12 (2006) (0)
- Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study (2021) (0)
- KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). (2021) (0)
- 3323 The GERMELATOX DeCOG-trial: The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspective (2015) (0)
- Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study (2022) (0)
- 149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC) (2021) (0)
- Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study (2021) (0)
- Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]. (2022) (0)
- Monocytes transduced with tricistronic lentiviral vectors in a closed bag system induce differentiation of loaded "SMART-DCs" for melanoma immunotherapy (2010) (0)
- P25 Prognostic value of SLN biopsy in malignant melanoma of the head/neck in comparison to trunk and extremities (2010) (0)
- Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma. (2021) (0)
- A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019) (0)
- Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study (2019) (0)
- Successful treatment of a metastatic melanoma with Talimogen laherparepvec (T‐VEC) in a liver transplant patient (2020) (0)
- [Rare tumor of the nasal cavity hidden in a nasal polyposis]. (2013) (0)
- Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study (2023) (0)
- Prognostic and predictive value of metformin in the EORTC 1325/KEYNOTE- 054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma (2023) (0)
- Supplementary Material for: Characterisation of Prognosis and Invasion of Cutaneous Squamous Cell Carcinoma by Podoplanin and E-Cadherin Expression (2016) (0)
- Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA. (2021) (0)
- Change in Fatigue and Correlations with Clinical Outcome in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib in the Bolt Study (2016) (0)
- Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA. (2022) (0)
- 1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO (2020) (0)
- Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. (2020) (0)
- [Medical tumor therapy]. (2011) (0)
- IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy. (2021) (0)
- Cutaneous Side Effects of combination Therapy with Sorafenib and Peginterferon - an Evaluation of the SoraPeg Study of the ADO (2011) (0)
- Real-world overall survival in advanced melanoma from the IMAGE study. (2016) (0)
- Safety data on adjuvant treatment of cutaneous melanoma patients with interferon-alpha2b and pegylated interferon-alpha2b: An interim analysis of 285 patients treated in Germany (2016) (0)
- 786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma (2022) (0)
- 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study (2020) (0)
- Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis (2021) (0)
- Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) (0)
- 828P Effectiveness and safety of dabrafenib and trametinib in patients with BRAFV600 mutated metastatic melanoma in the real-world setting: Final results of the non-interventional COMBI-r study (2022) (0)
- [Association Dermatologic Oncology (ADO). Treatment of advanced squamous cell carcinoma]. (2013) (0)
- Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients. (2012) (0)
- Contents Vol. 227, 2013 (2014) (0)
- 408 Up-regulation of the production of CCL18, a chemokine related to atopic dermatitis, by Th2 cytokines and by histamine H2- or H4 receptor agonists on human M2c- and M2a macrophages (2017) (0)
- Iconography : Alkaptonuric ochronosis: Report of two affected brothers (2011) (0)
- Histamine receptors in GtoPdb v.2021.3 (2021) (0)
- 1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS (2020) (0)
- PET/CT in malignant melanoma: a two‐tiered healthcare system? Updated healthcare situation regarding initial staging of malignant melanoma with PET/CT (2021) (0)
- Subject Index Vol. 205, 2002 (2002) (0)
- Mast cell tryptase generate C3a from keratinocyte derived C3: Implication for allergic skin inflammation (2007) (0)
- 261 Stimulation of the histamine 4 receptor increases the production of IL-5 in innate lymphoid cells (2016) (0)
- The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment. (2014) (0)
- Refinement of two distinct regions of allelic loss of the long arm of chromosome 11 in malignant melanoma (1998) (0)
- Aggressive gamma/delta T-cell lymphoma: successful therapy with encapsulated doxorubicin. (2021) (0)
- Abstract CT123: Aviscumine (ME-503), a plant protein with a novel mode of action, shows clinical activity in unresectable stage IV metastatic melanoma: data from a phase II trial (2016) (0)
- P97 Follicular and cystic eruptions under sorafenib therapy (2010) (0)
- P073. Dermatological follow-up of patients with non melanoma skin cancer after solid organ transplantation switched to an mTOR inhibitor (2011) (0)
- Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial (2018) (0)
- ReactionsAmplification Loop of Inflammatory Skin Keratinocytes: A Novel Autocrine Induction of C3 and CCL2 by C3a in (2006) (0)
- Randomized phase II study of the safety and efficacy of a human anti-αv integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results. (2009) (0)
- Histamine Activates Human Eosinophils via H2R and H4R Predominantly in Atopic Dermatitis Patients (2022) (0)
- Allelic loss of a defined chromosomal region of the long arm of chromosome 11 in sporadic malignant melanoma progression: 462 (1997) (0)
- Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter DeCOG study on 637 patients from the prospective skin cancer registry ADOREG (2023) (0)
- Abstract 5388: Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice (2020) (0)
- P66 Successful treatment of metastasizing squamous cell carcinoma with cetuximab (2010) (0)
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (0)
- The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment—Differences between the patient's and the physician's perspective. (2015) (0)
- 1137P Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study (2020) (0)
- [Adjuvant therapies in oncology: A critical benefit-risk assessment]. (2011) (0)
- Therapeutic use of erythropoietin in dermatooncology (2007) (0)
- Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study. (2021) (0)
- Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2023) (0)
- 26191 Time to onset of creatine kinase elevation in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study (2021) (0)
- 3338 Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE) (2015) (0)
- Well characterized antihistamine 4 receptor antibodies contribute to current knowledge of the expression and biology of the human and murine histamine 4 receptor (2012) (0)
- Axillary web syndrome as complication of axillary sentinel lymph node surgery (2022) (0)
- Newsletter No. 10/2010 (2010) (0)
- Fear of progression in patients with low-risk malignant melanoma. (2017) (0)
- Immunogenicity and Safety of the Prame Cancer Immunotherapeutic in Metastatic Melanoma: Phase I/II Dose Escalation Study (2012) (0)
- Corrigendum to 'IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy': Annals of Oncology 2021; volume 32: 696-697. (2021) (0)
- Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives (2022) (0)
- Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (0)
- A phase II multicenter study on CY-503 in the treatment of patients with unresectable stage IV metastatic melanoma after failure of previous chemotherapy. (2010) (0)
- PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma (2020) (0)
- [Systemic treatment of inoperable metastasized malignant melanoma]. (2016) (0)
- 30 years German Dermatologic Cooperative Oncology Group (DeCOG) (2021) (0)
- Acknowledgement to Referees for Dermatology 2002 (2002) (0)
- [Reduction of relapse in the radiation area by adjuvant lymph-node field radiotherapy in metastatic malignant melanoma patients at high risk of recurrence]. (2016) (0)
- Characterisation and outcome of RAC1 mutated melanoma. (2023) (0)
- Reply to E. Hindié. (2021) (0)
- P90 Remission of iatrogenic Kaposiʼs sarcoma after switch of immunosuppressive regimen to everolimus in a patient with myasthenia gravis (2010) (0)
- Contents Vol. 205, 2002 (2002) (0)
- 813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study (2022) (0)
- Evaluation of criteria in sentinel nodes of melanoma patients that predict involvement of non-sentinel nodes (2006) (0)
- Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS (2022) (0)
- Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry (2022) (0)
- Reply to assessment of capsular melanoma cell deposits in sentinel lymph nodes (2011) (0)
- Melanom (2023) (0)
- Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]. (2021) (0)
- Acknowledgement to referees 2013 (2014) (0)
- Reply to N. Rompoti et al. (2013) (0)
- 784O Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial (2022) (0)
- 26202 Antineoplastic therapy after discontinuation of sonidegib 200 mg in patients with advanced basal cell carcinoma: Results from the 42-month, randomized, double-blind BOLT study (2021) (0)
- Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI) (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ralf Gutzmer?
Ralf Gutzmer is affiliated with the following schools:
